US Stock MarketDetailed Quotes
DNLI Denali Therapeutics
- 21.930
- +0.470+2.19%
Trading Jul 22 11:43 ET
3.13BMarket Cap-23329P/E (TTM)
22.240High21.250Low183.82KVolume21.620Open21.460Pre Close4.00MTurnover0.15%Turnover RatioLossP/E (Static)142.61MShares28.75052wk High2.15P/B2.70BFloat Cap14.56052wk Low--Dividend TTM123.16MShs Float93.940Historical High--Div YieldTTM4.61%Amplitude12.320Historical Low21.773Avg Price1Lot Size
Denali Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -93.22%-113.62M | -46.29%-357.99M | -35.77%-98.66M | -53.14%-87.36M | -163.81%-113.17M | 18.45%-58.8M | -15.77%-244.72M | -10.95%-72.66M | -37.68%-57.05M | 20.88%-42.9M |
| Net income from continuing operations | 7.27%-101.8M | 55.45%-145.22M | -21.07%-119.47M | 3.82%-99.35M | 411.91%183.38M | -68.32%-109.78M | -12.19%-325.99M | -31.11%-98.68M | -22.12%-103.3M | 3.13%-58.79M |
| Operating gains losses | ---14.54M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -78.48%2.16M | 61.09%16.73M | -46.79%2.18M | 3.55%2.22M | 10.28%2.29M | 383.26%10.05M | 20.83%10.38M | 95.37%4.09M | -2.10%2.14M | -5.99%2.07M |
| Other non cash items | -9.12%-957K | -13.05%-3.72M | -12.22%-955K | -16.85%-957K | -11.14%-928K | -12.01%-877K | -10.19%-3.29M | -8.68%-851K | -4.73%-819K | -15.01%-835K |
| Change In working capital | -173.27%-15.81M | -1,106.52%-289.93M | 792.98%5.85M | -120.95%-4.41M | -3,103.79%-312.95M | 160.01%21.58M | -17.72%-24.03M | 104.08%655K | 16.30%21.04M | 47.59%-9.77M |
| -Change in prepaid assets | -948.97%-18.77M | -48.33%-4.09M | -336.97%-6M | -99.35%87K | 122.58%3.61M | -244.04%-1.79M | 78.55%-2.76M | 93.43%-1.37M | -17.01%13.37M | -11.40%-15.99M |
| -Change in payables and accrued expense | -87.43%2.96M | -61.50%5.08M | 429.07%12.23M | -128.72%-3.23M | -509.23%-27.44M | 433.07%23.51M | 56.36%13.19M | -69.93%2.31M | 54.46%11.23M | 83.42%6.7M |
| -Change in other current liabilities | ---- | ---379K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| -Change in other working capital | ---- | -743.05%-290.53M | --0 | 64.37%-1.27M | -60,259.71%-289.12M | 99.53%-141K | -120.04%-34.46M | 88.75%-283K | 32.67%-3.56M | 93.97%-479K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -93.22%-113.62M | -46.29%-357.99M | -35.77%-98.66M | -53.14%-87.36M | -163.81%-113.17M | 18.45%-58.8M | -15.77%-244.72M | -10.95%-72.66M | -37.68%-57.05M | 20.88%-42.9M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -388.80%-453.19M | 276.33%249.31M | 157.27%73.05M | 554.45%100.91M | 89.63%168.07M | 21.35%-92.72M | -553.78%-141.39M | -213.03%-127.56M | 129.09%15.42M | -9.13%88.63M |
| Net PPE purchase and sale | 22.83%-2.15M | 27.44%-12.94M | 53.91%-2.24M | 65.82%-2.07M | -102.21%-5.85M | 31.06%-2.79M | -109.80%-17.83M | -58.83%-4.85M | -222.67%-6.05M | -274.74%-2.89M |
| Net investment purchase and sale | -401.55%-451.04M | 312.25%262.25M | 161.35%75.28M | 379.65%102.98M | 90.02%173.92M | 21.00%-89.93M | -841.29%-123.55M | -225.52%-122.71M | 141.99%21.47M | -6.90%91.52M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -388.80%-453.19M | 276.33%249.31M | 157.27%73.05M | 554.45%100.91M | 89.63%168.07M | 21.35%-92.72M | -553.78%-141.39M | -213.03%-127.56M | 129.09%15.42M | -9.13%88.63M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 31,089.21%500.28M | -94.26%17.82M | -98.43%4.71M | -51.65%2.49M | 104.88%9.02M | 9.64%1.6M | 1,505.70%310.67M | 5,698.20%299.65M | 55.48%5.15M | -37.50%4.4M |
| Net common stock issuance | --499.25M | --0 | ---- | ---- | ---- | --0 | --296.22M | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | -36.28%1.02M | 23.28%17.82M | 36.93%4.71M | -51.65%2.49M | 104.88%9.02M | 9.64%1.6M | -25.29%14.46M | -33.51%3.44M | 55.48%5.15M | -37.50%4.4M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 31,089.21%500.28M | -94.26%17.82M | -98.43%4.71M | -51.65%2.49M | 104.88%9.02M | 9.64%1.6M | 1,505.70%310.67M | 5,698.20%299.65M | 55.48%5.15M | -37.50%4.4M |
| Net cash flow | ||||||||||
| Beginning cash position | -41.39%128.68M | -25.57%219.54M | 24.54%149.59M | -14.71%133.55M | -34.59%69.63M | -25.57%219.54M | -42.01%294.98M | -69.67%120.12M | -67.86%156.59M | -75.63%106.45M |
| Current changes in cash | 55.62%-66.53M | -20.46%-90.86M | -121.03%-20.91M | 143.97%16.04M | 27.49%63.92M | 20.48%-149.91M | 64.70%-75.43M | 198.37%99.43M | 59.98%-36.47M | -0.44%50.14M |
| End cash Position | -10.75%62.15M | -41.39%128.68M | -41.39%128.68M | 24.54%149.59M | -14.71%133.55M | -34.59%69.63M | -25.57%219.54M | -25.57%219.54M | -69.67%120.12M | -67.86%156.59M |
| Free cash flow | -87.97%-115.77M | -41.28%-370.93M | -30.16%-100.89M | -41.74%-89.43M | -159.92%-119.02M | 19.12%-61.59M | -19.40%-262.55M | -13.08%-77.51M | -45.69%-63.1M | 16.73%-45.79M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg